Clinical Trial Detail

NCT ID NCT03875079
Title A Phase IB Study To Evaluate Safety And Therapeutic Activity Of RO6874281, An Immunocytokine, Consisting Of Interleukin-2 Variant Targeting Fibroblast Activation Protein-A, In Combination With Pembrolizumab (Anti-Pd-1), In Participants With Previously Untreated Advanced And/Or Metastatic Melanoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Hoffmann-La Roche
Indications

mucosal melanoma

skin melanoma

Therapies

Pembrolizumab + RO6874281

Age Groups: adult senior

No variant requirements are available.